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1. ABSTRACT 
 
The purpose of my dissertation was to study the relationship between prognostic factors 
such as tumor cell nucleolar size, proliferation, extravascular matrix patterns, and 
dissemination of uveal melanoma, and to assess to what extent there is a relationship to 
metastasis. 
The secondary goal was to develop a multivariate model which includes MLN and cell 
proliferation in addition to MVD, and which would fit better with population-based, 
melanoma-related survival data than previous models.  
 
I. A population-based, retrospective cohort study of melanoma-related and all-cause 
mortality in 167 consecutive patients with enucleated eye due to choroidal and ciliary body 
melanoma from 1972 through 1981. MLN was measured from silver stained slides. MLN and 
extravascular matrix loops and networks were unrelated, independent predictors of survival. 
MLN and MVD were found to be partially interrelated. Multivariate models that included 
MVD in addition to MLN fitted better with observed melanoma-related survival than models 
that excluded MVD.  
 
II. A population-based, retrospective cohort study of 167 consecutive choroidal and ciliary 
body melanomas enucleated from 1972 to 1981. Mouse monoclonal antibody Ki-67 was used 
to identify proliferating cells. High cell proliferation index was associated with presence of 
epithelioid cells and with a higher risk of metastatic death independent of MLN, MVD, and 
presence of extravascular matrix loops and networks. 
  
III. A cross-sectional histopathological analysis of 37 metastases from corresponding 
primary choroidal and ciliary body melanomas enucleated from 1961 to 1981 was conducted. 
Hepatic metastases had more frequent epithelioid cells and a higher MVD than their 
corresponding primary tumors. Hepatic metastases tended to have a smaller MLN than the 
corresponding primaries. MLN in hepatic metastases was not associated with presence of 
epithelioid cells and MVD. The results suggest that MLN is not a useful marker for assessing 
prognosis after diagnosis of hepatic metastasis from uveal melanoma. 
 
IV. A population-based retrospective, cohort study of IGF-1R, 167 consecutive patients 
with choroidal and ciliary body melanoma enucleated from 1972 to 1981. More heavy 
Abstract 
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pigmentation, larger number of macrophages, and higher MVD were associated with a higher 
percentage of tumor area that was immunopositive for IGF-1R. Immunoreactivity for IGF-IR 
did not independently predict metastasis from primary uveal melanoma. Partial loss of 
antigenicity could not be ruled out as a confounding factor because no frozen sections were 
available. The results of earlier studies have likewise been inconsistent, suggesting that 
immunohistochemical determination of IGF-1R from formalin-fixed, paraffin-embedded 
specimens may not be practical as a routine test. 
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2. INTRODUCTION 
 
Uveal melanoma (UM) is the second most common primary intraocular cancer 
worldwide.1 It is a relatively rare cancer, but still the second most common type of primary 
malignant melanoma in humans.2 UM  is  a  slowly  growing  tumor,  and  gives  rise  to  distant  
metastasis mainly to the liver via the bloodstream.3   
UM arises from melanocytes of the choroid, the ciliary body, and the iris.4 These cells are 
of neuroectodermal origin and related to melanocytes found in the skin and the conjunctiva. 
The  choroid  is  the  most  common  location  for  UM,  then  the  ciliary  body  and  finally  the  
iris.5 Usually patients are asymptomatic in the early stages but as the tumor increases in size 
symptoms appear (e.g. blurred vision, visual field loss, floaters, eventual pain).5 Enucleation 
was the treatment traditionally offered to all patients with ciliochoroidal melanomas.6 With 
increasing evidence showing that eye preserving forms of treatment are not associated with 
increased mortality,7,8 enucleation has been largely replaced by radiotherapy, especially 
brachytherapy using Ru106 and I125 plaques. Since the late 1970s in institutions with access to 
a nuclear accelerator, charged particle radiation using protons9 and helium ions10 has been 
used. Other current forms of eye-preserving treatment of UM include stereotactic 
radiotherapy,11,12 endoresection,13,14 local transscleral resection,15-17 and transpupillary 
thermotherapy.18-20 
  UM differs from both cutaneous malignant melanoma (CMM) and conjunctival melanoma 
(CM) in that it almost always metastasizes hematogenously because there are no lymph 
vessels inside the eye and the orbit. Only in the rare case that the anterior sclera is penetrated 
by UM, may it disseminate through conjunctival lymphatics to the regional lymph nodes.21,22  
According to one study optic nerve invasion in UM is found in 1 in 20 patients.23 In more than 
90% of cases, the liver is involved when metastatic disease is diagnosed.3,24  
 About  40%  of  patients  with  UM  die  of  metastatic  disease  within  10  years  of  diagnosis,  
irrespective of the type of treatment.25,26 UM can be classified according to its cell type into 
spindle cell, mixed cell, and epithelioid cell melanomas.27,28 The prognostic implications of 
this classification have been known since 1931.27 Tumors containing epithelioid cells grow 
faster and have a poorer prognosis.27,29-31 
During the last decade, two main lines of research have aimed to achieve enhanced 
understanding of the metastasis process and accurate prognosis of patients with UM. One 
emphasizes the characteristics of tumor cells, particularly their nucleoli,32-48 and  markers  of  
proliferation,44,46,49-52 and the other the characteristics of tumor blood vessels. 29,30,40,41,46,53,54  
Introduction 
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Of several morphometric measurements, the mean diameter of the ten largest nucleoli 
(MLN) has become the most widely applied.33,35,42,46,48 A large MLN has consistently been 
associated with high likelihood of dying from UM.33,36-38,41,46,48 Many methods have been 
used to stain35,42 and sample the largest nucleoli33,35,39,42,48 and no agreement has yet been 
reached as to which combination is the best. 
Blood vessels are of paramount importance in metastasis of UM.24,53-57 Different 
extravascular matrix patterns can be seen in UM, like loops (of any size enclosing melanoma 
cells) and networks (which are composed of 3 back-to-back loops). This presence is 
associated with death from metastatic melanoma.29,53 However, the density of microvessels is 
also of prognostic importance.30,58,59  
MLN has been studied in general by many authors,39,41,42,46,48 but essentially none of them 
have studied both extravascular matrix patterns and MLN and their interrelationship, which is 
a main topic of my experiments.  To the best of my knowledge MVD has never been studied 
in relation to MLN.  
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3. REVIEW OF THE LITERATURE 
 
3.1 Uveal Melanoma as a Clinical Problem 
 
 
3.1.1 Epidemiology of Uveal Melanoma 
 
UM is the commonest intraocular malignancy in adult Caucasians, as they are at more than 
8 times greater risk of developing the disease than are Africans.60 According to recently 
published data from the European Cancer Registry, its age-standardized incidence in different 
European countries varied from 2 new cases in Spain and Southern Italy to 8 new cases in 
Norway and Denmark, and up to 6-8 new cases in Finland per million per year between 1983 
and 1994.61,62 The mean age at the time of diagnosis is between 50 and 60 years.60,63-65 
The frequency of UM depends on age, usually it is very rare in childhood, but its incidence 
increases in elderly after the age of 40-45, it reaches the apex in late middle age, usually 
between 55-60 years.26,60 The risk of UM increases with age, but in one study it seems to level 
off after the age of 70, more in females.65 Which differs from other adult cancers, as the risk 
increases with age.60 
According to various studies, 64% to 90% of UM originates in the choroid,63 and about 
10% and 3% in the ciliary body and the iris respectively.65,66 UM limited to the iris (iris 
melanoma) is normally discussed as a separate entity because of its favorable prognosis 
compared to melanomas.39,67,68 
UM is almost always unilateral. Less than 0.002% of UM patients have it bilaterally.81 
Clinical metastases are present in 0.2 – 2.5% of patients at diagnosis of primary UM.69-74 But 
up to 50% develop them later.26 
 
3.1.2 Etiology and Predisposition 
 
The etiology of UM remains unknown. Light blue eyes are also predisposing factors for 
increased risk for UM.60 People with lightly pigmented skin, hair, and irises are at a slightly 
increased risk of developing UM.66,75,76  
Even though lightly pigmented skin and light iris color are established risk factors, the role 
of sunlight and other ultraviolet light exposure which have been implicated in the etiology of 
cutaneous melanoma, is vague in UM.75,77-79 
Review of Literature 
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A slight predominance of male gender is evident from large series of UM, but the reason 
for this male predominance is unknown.60,64,65 No risk factors were associated with 
occupation, tobacco, and hormonal causes.60,75,80 
Congenital ocular melanocytosis (nevus of Ota), which is a pigmentary disorder where the 
number of melanocytes are increased in ocular tissues, is associated with an increased risk for 
UM.82  It has been noted also in patients with bilateral UM.81 .  
One tenth of UM develops from a previously diagnosed choroidal nevus.82-85 Singh et al.84 
estimated the prevalence of choroidal nevi to range from 4.6% to 7.9%. Whereas Kivelä et al. 
87 obtained confidence limits for the cumulative lifetime risk estimate based on the 
calculations of Singh et al,84 by estimating that the lifetime risk of UM from a choroidal nevus 
for a patient living to be 90 years old would be 0.04% (confidence interval [CI], 0.03%–
0.06%) by the age of 40 years, 0.28% by 60 (CI, 0.20%–0.34%), and 0.78% by 80 (CI, 
0.58%–1.0%). The lifetime risk estimate would approach 1%, which is not an insignificant 
figure.87 
The detection and treatment of choroidal melanoma early in its natural course is critical for 
optimal prognosis.86 Studies of tumor doubling time have indicated that metastasis from 
choroidal  melanoma  may  occur  quite  early  in  the  course  of  the  disease,  when  the  tumor  is  
about 3.0 mm in basal dimension and 1.5 mm in thickness.86,87 Clinical studies have shown 
that, at 5 years, metastasis occurs in 16% of patients with small choroidal melanomas (less 
than 4 mm thick), compared with 32% of those with medium-sized (4-8 mm thick) choroidal 
melanomas and in 53% of those with large (more than 8 mm thick) choroidal melanomas.86 
 The difficulty with early detection of choroidal melanoma relates to its clinical similarity to 
benign choroidal nevus. Factors that assist in differentiating small choroidal melanoma from 
choroidal nevus can be remembered using the mnemonic "TFSOM" (To Find Small Ocular 
Melanoma),88,89 where T = thickness greater than 2 mm, F = subretinal fluid, S = symptoms, 
O = orange pigment and M = margin touching optic disc. Any one of these factors increases 
the risk for growth, which often is a sign of malignancy, the more so when occurring together.  
Choroidal melanocytic tumors that display none of these factors have a 3% risk of growth 
into melanoma at 5 years and most likely represent choroidal nevi.88  Tumors that display one 
factor  have  a  38% risk  of  growth,  and  those  with  two or  more  factors  show growth  in  over  
50% of cases. Shields et al. calculated the relative risk for growth to be 1.9 for one factor, 3.8 
for 2 factors, 7.4 for 3 factors, 14.1 for 4 factors, and 27.1 for all 5 of their risk factors 
combined.88  
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  The COMS group has identified as additional risk factors larger basal diameter, and 
absence of drusen and retinal pigment epithelial changes adjacent to the tumor.90 Most tumors 
with  two  or  more  risk  factors  probably  represent  small  choroidal  melanomas,  and  early  
treatment is generally indicated. Therefore, ophthalmologists should be aware of the clinical 
factors that identify small choroidal melanoma thereby ensuring their patients early treatment 
and better prognosis.86 
UM in general is not hereditary, although some families with two or more patients have 
been reported.91,92 The most identified prognostic factor yet is the partial or total loss of 
chromosome 3, (monosomy 3).93,94 Other known chromosomal anomalies involve 
chromosomes 8 and 6. 
 
3.1.3 Clinical Diagnosis 
 
As UM grows slowly, the symptoms are usually not specific. The commonest symptoms 
are blurred vision (50-69%), visual field defect (9-30%) and photopsia (18-26%).65,66,95         
In 25-30% of patients the diagnosis is made during a normal exam, while a minimum 50% of 
them are asymptomatic.96 
Accuracy in the diagnosis of UM has improved in the past three decades. The diagnosis of 
UM is most often based on the typical appearance of the tumor on fundus examination and B-
scan ultrasound. The key clinical features are size, shape, pigmentation, exudative retinal 
detachment and orange lipofuscin pigment. (Figure A) 
In contrast to most other cancers, histopathologic specimens are rarely obtained for 
diagnosing UM.97 As this might increase the risk of local spread and vision loss, beside the 
sample might not represent the entire tumor.29 Fine-needle aspiration biopsy (FNAB) is 
nevertheless used to confirm difficult diagnoses.29,98-102 Moreover,  today  biopsies  are  also  
performed for prognostic purposes,97 thereby increasing the diagnostic accuracy.103   
Clinical diagnosis might be difficult, differentiating small melanoma from nevi.97,104 
Documented growth is usually required to confirm the diagnosis of small melanomas, despite 
the fact that nevi might grow slowly during follow-up period.97,104,105 
The inner parts of the tumor gives a low-reflective shadow in B-scan ultrasound.106-108 
(Figure B) This examination may detect extrascleral extensions as well.106,109 
Transillumination may show tumor edges extending anterior to the ora serrata, which can be 
useful to detect melanomas in the ciliary body. Although, it is best seen with high-frequency 
ultrasound.106-108 
Review of Literature 
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Figure A: 
 
Typical fundus photograph of 
the left eye in a patient with 
UM, showing a pigmented 
lesion and orange lipofuscin 
pigment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B: 
 
B-scan ultrasonography 
showing a low-reflective 
tumor in a patient with UM.  
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Fluorescein angiography (FAG) is now rarely used, but it has been used earlier to identify 
the double circulation pattern typical of UM,110 and is useful in the differential diagnosis of a 
vascular tumor. Indocyanine green angiography (ICG), a more recent diagnostic method,111 
has been shown to be superior to FAG in imaging tumor vascularization.112 
     Optical coherence tomography (OCT) may provide information about the retinal structure 
overlying prominent tumors and the extent of adjacent retinal detachment.113 In  its  present  
state of development, OCT is especially valuable in the differential diagnosis of small 
choroidal tumors in detecting incipient retinal detachment. Its potential value for the follow-
up of shallow tumors needs further investigation.113 
 
3.1.4 Histopathological Diagnosis 
 
Histologic factors play an important role in the diagnosis and estimation of prognosis in 
UM, and staining techniques have developed greatly in recent years.31 The tumors are 
classified according to cell type by the modified Callender classification to; spindle cell, 
mixed cell, and epithelioid cell melanomas (Figures C, D). Spindle cell melanomas grow 
more slowly and have better prognosis than other types.114 Epithelioid tumors show a faster 
growth and usually metastasize.31 
 
 
 
Figure C: 
Hematoxylin-eosin slide showing a predominantly 
spindle cell UM with single epithelioid cells. 
  
 
 
 
 
 
 
Figure D: 
Hematoxylin-eosin slide showing epithelioid cell UM. 
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3.1.4.1 Extravascular Matrix Patterns 
 
The presence of extravascular matrix patterns (Figure E) in UM and their association with 
metastatic death are well established.54 
Tumor extravascular morphology in UM was first described by Folberg et al. in 1992.54 
Folberg classified “vascular patterns” into nine morphological types54: The normal pattern 
consists of normal uncompressed choroidal vessels. The silent pattern contains no apparent 
tumor vessels. The straight pattern is composed of randomly oriented straight vessels that are 
not linked with each other. The parallel pattern includes straight vessels that are arranged 
parallel to one another. The parallel with cross-link pattern contains vessels of parallel pattern 
that are also linked to each other. The arcs and arcs with branching patterns are curves of 
vessels  that  failed  to  form  loops.  The  loop pattern consists of vessels that are completely 
closed. The diameter of loops ranges from 14 µm to 157 µm in different tumors.54 The 
network pattern is composed of at least three back-to-back closed loops. By definition, if 
networks  are  present,  loops  are  present.  Of  the  nine  different  patterns  described,  closed  
extravascular matrix loops and networks have been most extensively studied.29,40,53-56,115-121 
 
 
Figure E: 
Periodic acid-Schiff slide showing extravascular matrix 
patterns of the network type in UM. 
 
 
 
 
Analysis  of  some  of  these  patterns  by  multivariate  models  has  shown  them  to  be  better  
prognostic indicators than conventional clinical or histopathological characteristics,122 
including tumor size,54,123 involvement of the ciliary body,40,54 the cell type,54,123 and the mean 
diameter of the 10 largest nucleoli.39 
Melanocytic nevi do not have any parallel with cross-linking, arcs, arcs with branching, 
loops, or networks, consistent with the finding that these patterns may be associated with 
melanoma.118,119,124,125 
In a study of 40 patients, those who survived more than 15 years had more often the 
normal and silent patterns than those who died of the metastatic disease.54  
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A follow-up study of 234 patients showed melanoma-related mortality to be higher among 
patients with parallel vessels, parallel vessels with cross-links, arcs, arcs with branching, 
loops, and networks than among patients without these extravascular matrix patterns.29,40 
These patterns were found more often in ciliary body than in choroidal melanomas.40 Loops 
and networks are particularly useful in differentiating spindle cell and choroidal melanomas 
with better and worse prognoses.53 
Extravascular matrix patterns are also seen in cutaneous melanoma. Parallel vessels with 
cross-linking or networks carried independent prognostic significance in multivariate models 
when adjusting for the known strong prognostic indicator, tumor thickness.126 Tumor cells of 
UM and metastatic cutaneous melanoma are able to form extravascular matrix patterns, in 
particular extravascular matrix loops and networks, in vitro without the presence of 
endothelial cells.117 
 
3.1.4.2 Microvascular Density (MVD) 
 
Microvascular density (MVD) is a morphologic measure of the densest area  of  
vascularization.127,128 (Figure  F) The number of immunolabeled microvessels counted from 
the densest vascularized area called a “hot spot” is associated with an increased risk for 
metastatic death.55 High MVD is taken as evidence of active angiogenesis in many types of 
cancer.127,129 including tumors that frequently spread through the lymphatic route, such as 
breast cancer.128,130,131 Some studies on MVD have failed to document a relationship with 
metastatic death with other cancers.132,133  
  Some studies have shown that high MVD is associated with shorter survival in UM. Foss 
et al. first reported this relationship.58 They did not find any relationship between 
extravascular matrix patterns and survival in their data set after adjusting for MVD.134 MVD 
was higher in tumors with extravascular matrix loops and networks, suggesting that the effect 
of extravascular matrix patterns on prognosis may be secondary to high MVD.134 On the 
contrary, Mäkitie et al. found in a population based study of 167 patients a statistically 
significant association between high MVD and the presence of extravascular matrix loops and 
networks, presence of epithelioid cells, and largest basal tumor diameter.30 This  was  
confirmed by Chen et al.59 
 
Figure F: High MVD in UM evaluated from a “hot spot” 
by antibodies to CD34 epitope. 
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3.1.4.3 Macrophages 
 
Presence of tumor infiltrating macrophages is statistically associated with high MVD 
rather than with loops and networks.55,59,135 High numbers of macrophages also predict a high 
likelihood of metastasis from UM. It is unknown whether macrophages are causally related to 
tumor progression and formation of extravascular matrix patterns e.g. by secreting growth-
promoting cytokines, or whether they are merely scavengers that reflect high cell turnover in 
rapidly growing, aggressive melanomas.136  
 
3.1.4.4 Mitotic Count 
 
Some authors have reported an association between mitosis and high mortality rates in 
UM.31,137,138 The mitotic count of UM correlates with the risk of metastatic death.139 
Conventionally, mitotic count is established by counting the number of mitoses per 40 
high-power fields (HPF) using the 40x objective in HE stained sections.137 However, Agni et 
al.139 recently reported that because of difficulties in identifying mitotic count reliably with 
HE stained sections, they now identify mitotic count by using immunohistochemistry with the 
mitosis-specific marker Phospho-Histone H3 Ser10 (PHH3).139  
 
3.1.4.5 Cell Proliferation Markers 
 
PC-10 and Ki-67 are known antibodies for detecting proliferation of tumor cells, PC-10 
monoclonal antibody detects an epitope on the proliferating cell nuclear antigen, a 36-kDa 
nuclear protein associated with the cell cycle.140 The  concentration  of  the  proliferating  cell  
nuclear antigen increases during the S-phase of the cell cycle,141 and flow cytometry studies 
confirm that the PC-10 clone may be used as an S-phase marker.142 The Ki-67 detects cells in 
late Gl, S, G2, and M phases of the cell cycle; it does not detect cells in the G0 phase.143,144 
Some studies have reported a prognostic association between proliferating tumor cells and 
mortality in UM and in other cancers.50,51,145 A high proportion of PC-10 and Ki-67 
immunopositive UM cells were associated with decreased survival.50,51,138,145 Seregard et al. 
found that a high fractions of PC-10 immunopositive tumor cells are associated with a 40% 
increase in 10-year melanoma-related mortality.51 They also found that a high PC-10 count 
was an independent prognostic factor by multivariate analysis adjusted for LBD, presence of 
extravascular matrix patterns, and MLN.46  
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3.1.4.6 Nuclear Morphology 
 
Many papers have indicated that cytomorphometric parameters, such as the nucleolar area 
(Figure G) measured from selected cells of UM are associated with higher 
mortality.25,36,38,42,146 In general, MLN was an independent prognostic parameter in 
multivariate models, among different research laboratories.36,38,42 Different methods of 
measuring MLN are still a matter of controversy. Currently silver-stained sections are 
considered superior to HE-stained sections.48  
Moshari et al. summarized and compared the various histologic methodologies for using 
nucleoli to assess the malignant potential of UM. He found that the silver-stained nucleoli 
define the nucleolar boundaries more clearly.48 
Pe’er et al. reported that the network and the parallel vessels with cross-link extravascular 
matrix patterns were more powerful prognostic indicators than cytomorphometric indices, 
such as the mean of the ten largest nucleoli in their data set.39 But they were unable able to 
confirm the use of the mean of the ten largest nucleoli as a significant prognostic factor in the 
outcome of patients whose eyes have been removed due to ciliary body or choroidal 
melanomas.39 Gamel et  al.  reported that MLN from a single routine hematoxylin and eosin-
stained section can be a useful cytologic index of the malignant potential of uveal 
melanomas.36 Sørensen et al. in their multivariate models found that MLN and nucleolar 
volume pleomorphism had independent prognostic value.37 Mclean  et  al.  have  published  on  
the importance of large nucleoli in predicting patient outcome.42  
Seregard and coauthors found that the PC-10 count retains a prognostic value in UM when 
adjusting for the effect of the MLN and diverse vascular patterns.46  
Bechrakis et al. described cytologic transformation and tumor progression in a series of 15 
UM  which  was  treated  by  primary  transscleral  local  resection  without  primary  adjuvant  
treatment, and needed enucleation because of local tumor recurrence. They found that there 
was an increase in the epithelioid cells in the tumor recurrence group, and that the nucleolar 
area was significantly increased in all cases, which demonstrates that in UM cytologic 
phenotype changes considerably even after a relatively short time, resulting in increased 
mortality.147 
 
Figure G: 
Nucleoli of UM evaluated using the silver staining 
method. 
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3.1.4.7 IGF-1R 
 
The insulin-like growth factor (IGF) family consists of ligands (IGF-I, IGF-II, insulin), and 
several receptors (including IGF-1R). Members of this family regulate key cellular activities 
and they also play an important role in the development and progression of cancer.148 
IGF-1 and its receptor (IGF-1R), a plasma membrane glycoprotein composed of four 
subunits linked by disulfide bonds,149,150 are involved in tumorigenesis and may also protect 
against apoptotic cell death.150,151 In  a  series  of  papers,  a  relationship  between  IGF-1R  
expression and metastatic death from UM has been proposed.152-156 The experiments also 
suggested that the viability of UM cells would be decreased after inhibition of IGF-1R 
activity,155,156 making this a particularly interesting tumor marker. 
The fact that the liver is the principal target organ for metastasis in UM157 raises the 
suspicion that hepatic environmental factors such as the growth factors largely produced in 
the liver – hepatocyte growth factor (HGF), epidermal growth factor (EGF), insulin like 
growth factor-1 (IGF-1) – and their receptors might have a role in the homing and survival of 
these metastatic melanoma cells. 
 
3.1.4.8 TNM Classification 
 
The Tumor, Node, Metastasis (TNM) System is an international classification developed in 
collaboration by the American Joint Committee on Cancer (AJCC) and the Union for 
International Cancer Control (UICC) to aid in the management, research and assessment of 
prognosis for different forms of cancer. The TNM classification for UM has evolved in recent 
and the latest edition will be used worldwide.158 The current TNM 7th Edition provides 
clinical useful definitions of tumor size, location, and metastatic disease for almost all eye 
cancers including UM. The use of this classification will allow ocular oncologists to compare 
treatments on equivalently sized and ‘‘staged’’ tumors. The introduction of this staging 
system will improve participation in clinical trials and compliance with cancer center 
status.159 
For   tumors  of  the  iris  there  are  four  T  categories  based  on  tumor  extension  to  the  iris,  
ciliary body, choroid or both, scleral extension, association with glaucoma, and extrascleral 
extension. For ciliary body and choroidal tumors there are four T categories and four 
subcategories (Tables A and B), with or without ciliary body involvement and extraocular 
involvement. The regional lymph node involvement is marked with N1, and distant metastasis 
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with M1. The latter is divided into 3 groups, largest diameter of the metastasis 3 cm or less, 
between 3.1 cm to 8 cm, and more than 8 cm.159,160 
 
Table A: TNM classification of ciliary body and choroidal melanomas according to 
anatomical extent 
T1     Tumor size category 1  
T1a     T1 category without ciliary body involvement or extraocular extension 
T1b     T1 category with ciliary body involvement 
T1c     T1 category without ciliary body but with extraocular extension ? 5 mm  
T1d     T1 category with ciliary body and extraocular extension ? 5 mm 
 
T2     Tumor size category 2  
T2a-d     T2 category and similar sub-categories as for T1 
 
T3     Tumor size category 3  
T3a-d     T3 category and similar sub-categories as for T1 
 
T4    Tumor size category 4  
T4a-d    T4 category and similar sub-categories as for T1 
T4e    Any tumor size category with extraocular extension > 5 mm  
 
 
Table B: TNM staging of uveal melanoma according to prognostic groups  
Stage I   T1a   N0  M0   
 
Stage IIA   T1b-d  N0  M0 
   T2a   N0  M0 
 
Stage IIB   T2b  N0  M0 
   T3a   N0  M0 
 
Stage IIIA  T2c-d   N0  M0       
   T3b-c  N0  M0 
   T4a   N0  M0 
 
Stage IIIB   T3d  N0  M0 
   T4b-c  N0  M0 
 
Stage IIIC  T4d-e  N0  M0       
 
Stage IV   Any T  N1  M0  
    Any T   Any N  M1a-c 
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3.1.5 TREATMENT 
 
 
3.1.5.1 Enucleation  
 
 
Enucleation used to be the only treatment for UM until the late 1960’s, when eye-
conserving methods were introduced.161 Enucleation is still an option in many developing 
countries and for some patients when the tumor has progressed to a large size and the chances 
of saving the eye and vision are limited.104 
In 1978, Zimmerman et al. published an article suggesting that enucleation accelerated 
metastatic death by physically disseminating tumor cells from the eye into the general 
circulation. This hypothesis was based largely on the observation that the mortality rate peaks 
in the second post-operative year.162  
Enucleation has some advantages. It is an easy procedure to perform at most ophthalmic 
units. It prevents local tumor recurrences if there has been no extrascleral extension prior to 
surgery.163 Besides, it provides the ophthalmic pathologist with large samples for future 
analysis. The disadvantage is an immediate loss of the eye and remaining vision.164 No 
significant difference in survival has been observed between equivalent groups of patients 
with a primary choroidal or ciliary body melanoma treated by enucleation versus plaque 
radiation therapy.7,165-167 
 
3.1.5.2 Radiotherapy 
 
Radiotherapy is a type of treatment given either through episcleral radioactive plaques   
(Co60,  I125, Ru106, Ir192 or Pd103)  or  through  accelerated  particles  such  as  protons  or  helium  
ions. The advantage of these methods is to preserve some vision in the affected eye, especially 
in eyes with small tumors.168-171  
In  general  UM  is  quite  resistant  to  high  doses  of  radiation,  which  leads  to  visual  
complications because of accompanying cataract, radiation retinopathy, and optic 
neuropathy.168,170,172 Recurrence rate of UM post radiotherapy ranges from 5 to 10% over 5 
years,173,174 local recurrences may also increase the risks of distant metastasis up to five 
times.173,174 
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3.1.5.3 Proton Beam Therapy (PBT)  
 
PBT delivers a homogenous dose of radiation within the tumor volume, whereas in 
brachytherapy the tumor base receives several times the dose of the tumor apex.175 PBT 
avoids any risk of radiation exposure to the surgeon’s hands.175 In some centers, it is selected 
for all UM undergoing radiotherapy treatment.175 It is expensive compared to brachytherapy, 
and may cause significant side effects in ocular and extra-ocular structures.176 It is usually 
used  for a special group of patients.176 It permits radiotherapy in larger tumors not suitable 
for brachytherapy and may be preferred for tumors located close to the optic disc or 
macula.175  
 
3.1.5.4 Stereotactic Radiotherapy 
 
Stereotactic radiotherapy, which is based on collimated beams of gamma rays or gamma-
knife electronic linear accelerator which converge to an exact volume.12,177,178 It can be used 
to treat small, medium sized and some large UM.12,179 
 
3.1.5.5 Transpupillary Thermotherapy (TTT)  
 
In selected cases primary TTT may help to preserve vision by arresting the progression of 
tumor growth. The trade-off between potential loss of vision and the risk of local tumor 
recurrence and metastasis must be carefully discussed with each patient. Current data indicate 
that TTT as primary therapy even for small choroidal melanocytic lesions is not as effective 
as radiation.180 The overall effect of primary TTT on survival is not currently known.180,181 
 
3.1.5.6 Resection 
 
Transscleral resection or endoresection is another method of treating UM.14,104 The tumor 
is removed through a scleral incision or vitrector, respectively, the advantage of this method 
being that only limited radiation from a plaque used as a safety measure is needed, and 
therefore risk of neovascular glaucoma and optic neuropathy is lower, the chances of 
preservation of vision are higher.182 Bechrakis et al. recently has reported that transscleral 
resection could be an alternative to enucleation for the treatment of large UM,15 and if 
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combined  with adjuvant radiotherapy could be the treatment of choice in cases of large 
tumors.183 
This method also has disadvantages as it carries a higher risk of local recurrence.14  
Besides, it requires a special type of hypotensive anesthesia which is not safe for all patients. 
 
3.2 Prognosis 
 
The 10-year cumulative melanoma-related survival is about 60%, and then decreases about 
1% each year.25,31,184 Death  is  mainly  due  to  metastasis,  which  in  some  series  has  been  
documented even decades after enucleation.185,186 UM has a predilection to metastasize to the 
liver.3,187-189 In 50% of cases the liver is the only organ involved in metastasis.3,189,190 Annual 
screening with liver function tests and abdominal ultrasound will identify 59% of patients 
while they are still asymptomatic.3 Other more frequent sites involved are skin, lung, bone 
and the central nervous system (CNS).3,188,190-192  
The median expected survival after metastasis is about 12 months, although there have 
been some reports regarding slower growing metastases in patients who have survived 
between 36 and 48 months.193,194 
Treating metastatic UM is frequently disappointing.195 Chemotherapy, 
chemoimmunotherapy,  and chemoembolization may have increased survival to a mean of 
over one year.193,195-199 This may, however, be due to lead time bias.200 Patients treated with 
surgery for slow growing metastases have rarely survived for long periods.194,201,202  
The course of UM is modulated by both tumor and host,  some patients with large tumor 
may live longer than those with smaller tumor; this applies to other prognostic factors as well. 
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4. AIMS OF THE PRESENT STUDY 
 
This study was undertaken to determine the relationship between microvessels, tumor 
nucleoli and cell dissemination in malignant UM, to add to what is known about them 
individually from earlier studies. What is not known is how they independently relate to the 
growth rate of the tumor compared to the ability of tumor cells to generate micrometastasis.  
While  the  work  for  this  dissertating  was  ongoing  several  studies  on  Insulin-like  Growth  
Factor  1  Receptor  (IGF-1R)  in  UM  were  published,  but  from  only  two  laboratories,  thus  it  
was important to check whether it holds true for other material as well. 
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5. MATERIALS AND METHODS 
 
 5.1 Patients 
 
There were a total of 167 patients, 76 (46%) were males and 91 (54%) were females. Mean 
age at enucleation was 58 years (median, 61 years; range, 13-95 years). UM was choroidal in 
126 (76%) globes and ciliochoroidal in 40 (24%) globes, of which 4 (10%) were located in 
the ciliary body and were confirmed by histopathology.  
 
5.1.1 Eligibility Criteria and Follow-up (I, II, and IV)  
 
A cross-sectional, population-based cohort of patients with UM previously used for 
analysis of extravascular matrix loops and networks was studied. 
A total of 170 consecutive patients with UM were identified from the medical records of 
the Ophthalmic Pathology Laboratory, Department of Ophthalmology, Helsinki University 
Central Hospital. All patients with a choroidal or ciliary body melanoma from the period 1972 
to 1981were included in the study. During that period, enucleation was the only treatment 
modality for patients with UM except those with the smallest melanomas during this period.  
These were first followed-up for growth, making the series essentially population-based and 
unselected. All enucleated globes were submitted to the Ophthalmic Pathology Laboratory.  
Three patients were excluded from the analysis: one patient with cutaneous melanoma 
metastatic to the choroid, one patient due to removal of the eye with choroidal melanoma in 
autopsy, and one patient because of a miscoded iris melanoma. Therefore, 167 patients with 
choroidal  or  ciliary  body melanoma were  left  for  study.  Inclusion  criteria  were  that  at  least  
50% of the primary tumor remained in the tissue block and the remainder was not entirely on 
the vitreal side of Bruch’s membrane.30   
Complete follow-up data for each patient was gathered in December 2001 from the Finnish 
Population and Cancer Registries, patient records, from pathology laboratories, and death 
certificates.  
In order to analyze melanoma-related mortality more reliably than in a cancer registry 
based-analysis, an attempt was made to differentiate as reliably as possible all melanoma 
deaths from other deaths.26 
The cause of death was validated by reviewing all patient records relating to malignant 
tumors and death, crosschecking with the Finnish Population and Cancer Registries, and by 
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acquiring all histopathological material available from primary tumors, metastases, and 
second cancers.30,53,136 The study followed the principles of the Declaration of Helsinki and 
was approved by the Institutional Review Board. 
 Histopathological diagnosis of all amelanotic primary tumors, all nine secondary cancers, 
and 49 of 53 specimens of metastases from UM were previously reconfirmed by 
immunohistochemistry.26,30,53 
To  improve  the  accuracy,  all  tumor  deaths  irrespective  of  the  primary  site  and  all  other  
non-tumor deaths were reviewed. The clinical reliability of the cause of death was evaluated 
in the following descending order: autopsy, surgical biopsy, fine-needle biopsy, imaging, and 
clinical charts. 
 
5.1.2 Eligibility Criteria and Follow-up (III)  
 
All patients with a choroidal and ciliary body melanoma enucleated between 1962 and 
1981 and which metastasized were eligible to increase the number of biopsied metastases. 
Inclusion criteria were that at least 50% of the primary tumor remained in the tissue block and 
the remaining part was not entirely on the vitreal side of Bruch’s membrane,30 and that one or 
more core needle biopsy, biopsy or autopsy specimens, with a surface area of at least 0.35 
mm² was available from hepatic metastases. This is roughly the minimum area needed to 
measure MVD.30 
During the study period, 292 consecutive patients had an eye with a choroidal and ciliary 
body melanoma removed, and 145 of these patients developed metastases that were 
cytologically or histologically confirmed in 92 of them; 48 pairs of primary tumors and 
hepatic metastases fulfilled the inclusion criteria in a prior study.203   
Of the 48 specimens, only 37 were available for restaining, because one of the primary 
tumors was necrotic, four had indistinct nucleoli, and six had very small specimen samples to 
be analyzed. (Table 1; Paper III) 
Of the 37 sections, 1 (3%) was a core needle biopsy, 12 (32%) were surgical biopsies, and 
24 (65%) were autopsy specimens. The metastases had been detected by liver imaging or 
laparoscopy after they caused symptoms. The original size of the biopsied and autopsied 
metastases was not recorded and, except in one case, the entire metastasis was not present in 
the specimen. The largest diameter in the biopsy was measured from the sections with a 
caliper. The ranges of specimen sizes for core needle biopsy, surgical biopsy, and autopsy 
were 1.5 mm, 9 mm (range, 4-19), and 20 mm (range, 6.5-25) respectively. 
Materials and Methods 
 30 
 
5.1.3 Bleaching of Melanin 
 
Potassium permanganate bleaching is suitable for the removal of melanin prior to 
hematoxylin-eosin (HE) and periodic acid-Schiff staining.29,54 This  method  was  used  in  the  
analysis of extracellular matrix patterns. 
Chromogens, such as 3',3'-diaminobenzidine tetrahydrochloride and 3-amino-9 
ethylcarbazole that yield a dark brown reaction and a brick red reaction product respectively 
cannot be differentiated easily from melanin in pigmented tumors.204 If bleaching is 
performed prior to immunoperoxidase staining it often alters antigenicity and a significant 
number of antibodies fail to work properly.205 
Thus, in order to visualize positive immunoreaction in pigmented tumors reliably, we 
bleached melanin by incubating the sections in 3.0% (v/v) hydrogen peroxide and 1.0% (wt/v) 
disodium hydrogen phosphate for 18 h at room temperature after immunostaining.206 This 
procedure obviates any change in antigenicity due to the bleaching.206 
 
5.1.4 Assessment of Nucleolar Size (silver staining)  
 
Both HE staining33,35-39,41,42,46 and silver staining,42,48 originally designed for labeling 
nucleolar organizing regions, were used to identify nucleoli for measurement. The silver stain 
provides high contrast between nucleoli and other structures, allowing accurate discrimination 
of nucleoli.42,48 A comparative study found that measurements from silver-stained slides were 
easier to make and provided prognostically more significant results than those from HE 
slides.48 The  most  frequent  field  selection  for  sampling  has  been  a  5-mm-long  linear  strip  
from the center of the melanoma. Linear sampling has been reported to be comparable to 
scanning nucleoli from the entire tumor section in predicting outcome.48 For these reasons, I 
chose silver staining and linear sampling. 
 Sections were cut at 5 µm on chromium-gelatin–treated glass slides207 and randomly 
coded. The code was broken only after all MLN measurements had been obtained. After 
deparaffinization, the sections were bleached with 0.25% (wt/vol) potassium permanganate 
for 1 hour and 5.0% (wt/vol) oxalic acid in distilled water for 5 minutes. 
One-step silver staining was performed using two solutions42,48 first, 2.0% (wt/vol) gelatin 
(Bacto Gelatin; Difco Laboratories, Detroit, MI) and 0.88% (vol/vol) formic acid in distilled 
water; second, 50% (wt/vol) silver nitrate in distilled water. The solutions were mixed 1:2 in 
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the  dark  and  poured  into  a  dish  to  cover  the  specimens  for  30  minutes.  The  sections  were  
washed in distilled water and dehydrated, and coverslips were mounted (Mountex; Histolab 
Products AB, Göteborg, Sweden).  
Each slide was examined under a light microscope (BH-2; Olympus, Tokyo, Japan) at 20X 
magnification  to  orient  the  central  longest  axis  of  the  tumor  parallel  to  the  tumor  base  for  
digital photography (DP-10; Olympus). A photograph under low magnification was first taken 
for documentation of orientation. A series of color photographs under 400X optical 
magnification were obtained to image the nucleoli along this axis. A 5-mm strip was 
photographed, divided into 25 slightly overlapping images (resolution, 1280 X 1024 pixels, 
image area 218 X 75 µm). If the tumor was less than 5 mm by largest basal diameter (LBD), 
the entire central axis of the tumor was photographed.  
From each of the 25 photographs, the largest nucleoli were measured by image-analysis 
software (Olympus DP-10 Soft, ver. 3.0; Soft Imaging System GmbH, Münster, Germany). A 
strip one screen high at 300% digital magnification (final magnification on screen, X4700; 
corresponding to 41 µm) was scanned from the top of each photograph. Measurements were 
taken along the longest axis of the nucleoli. The number of nucleoli measured was one to five 
per image (13 to 80 per section; total area, 0.205 mm²). The mean of the 10 largest nucleoli 
was calculated. 
 The images from a randomly drawn set of 63 (50%) slides were remeasured after 6 weeks 
by the same observer, and a second observer also graded these same images to assess 
intraobserver and interobserver variability respectively. 
 
5.1.5 Immunohistochemistry 
 
The paraffin blocks were cut at 5 µm thickness. The immunohistochemical staining was 
done using a commercial version (Vectastain ABC Elite Kit, Mouse IgG, Vector Laboratories, 
Burlingame, CA) of the avidin-biotinylated peroxidase complex (ABC) method.53,208 The 
sections were deparaffinized in xylene and rehydrated in an ethanol series. 
When heat-induced antigen retrieval was needed, the specimens were placed in a jar filled 
with 10 ml sodium citrate buffer (pH 6.0, adjusted with 2 N NaOH), and heated in a water-
bath for 15 min at 95°C.209 The jar was allowed to cool for 20 min at room temperature after 
heating.  
Endogenous peroxidase activity was consumed by treating the sections for 30-min in 
methanol containing 0.5 % (v/v) hydrogen peroxide. They were then incubated with normal 
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horse or goat serum (Vectastain ABC Elite Kit, diluted 1:50) in a moist chamber for 30 min at 
room temperature. All immunoreagents were diluted with PBS (pH 7.0) containing 2.0% 
(wt/v)  bovine  serum  albumin  (BSA;  E.  Merck,  Darmstadt,  Germany).  The  sections  were  
washed three times for 10 min in PBS between each step. Incubation with the primary mAbs 
was carried out in a moist chamber overnight at 5°C. Subsequently, the sections were 
incubated with biotinylated horse anti-mouse or goat anti-rabbit IgG antiserum (Vectastain 
ABC Elite Kit; diluted 1:200) and then with (the) ABC (Vectastain ABC Elite Kit reagents A 
and B, both diluted 1:160) in a moist chamber for 30 min at 37°C. The peroxidase reaction 
was developed with 3',3' diaminobenzidine tetrahydrochloride (Sigma; 150 mg in 16 ml 
dimethylsulfoxide and 200 ml PBS containing 0.03% (v/v) hydrogen peroxide). Coverslips 
were mounted with Aquamount (BDH Chemicals, Poole, UK). 
 
5.1.6 Assessment of Microvascular Factors 
 
Closed extravascular matrix loops and networks consisting of at least three back-to-back 
loops,  were identified according to Folberg et  al.29,54 from sections bleached with potassium 
permanganate and oxalic acid and stained with periodic acid–Schiff without counterstain.30,53 
They were viewed under a green filter (Wratten No. 58; Eastman Kodak, Rochester, NY). 
Loops of all sizes were taken into account. 
 Microvessels  were  identified  with  the  monoclonal  antibody  QBEND/10  to  the  CD34  
epitope of endothelial cells (lot 121202; Novocastra Laboratories, Newcastle-upon-Tyne, UK; 
diluted 1:25).210 They were counted at 400X magnification from the most highly vascularized 
area (hot spot), using an eyepiece with an etched graticule corresponding to 0.313 mm² (WK 
10x/20L-H; Olympus).30 Any immunolabeled element, clearly separate from adjacent ones 
and totally inside the graticule or touching its top or left border, was counted as a 
microvessel.134 
 
5.1.7 Assessment of Ki-67 Immunoreactivity 
 
Mouse monoclonal antibody (mAb) Ki-67211 (clone 7B11, lot 30276010C; Zymed 
Laboratories, San Francisco, CA, USA), diluted 1:10, was used for identifying cells in late Gl, 
S, G2, and M phases of the cell cycle; it does not detect cells in the G0 phase.143 Another Ki-
67 antibody (clone MIB-1, lot 012(201), DAKO A/S, Glostrup, Denmark), tested in pilot 
series, did not produce an equally good immunoreaction. An mAb to proliferating cell nuclear 
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antigen (clone PC10, lot 71K4870, Sigma Chemical Co., St. Louis, MO, USA) produced 
unduly heavy background. The slides were stained in duplicate and examined under a light 
microscope (magnification, 20X). Cells with immunopositive nuclei were counted. 
 To determine the cross-sectional area of the tumor, the slides were photographed with a 
digital camera (CoolPix 950, Nikon Corporation, Tokyo, Japan) and tumor area was measured 
with image analysis software (Olympus DP-10 Soft). A set of the same slides was stained 
using HE. Each slide was photographed under a light microscope at 20X magnification. 
Nuclei per image area (width 432 µm, height 346 µm) were counted using the image analysis 
software.  
Two orbital lymphomas processed identically to the melanoma slides were used as external 
positive controls in the immunohistochemical staining. A large number of proliferating cells 
was found in both. In addition, limbal corneal epithelium was used as an internal positive 
control, whenever present in the slide 
 
5.1.8 Assessment of IGF-1R Immunoreactivity 
 
Rabbit polyclonal antibodies against a peptide mapping at the N-terminus of IGF-1R? (N-
20; sc-712, Santa Cruz Biotechnology, CA, diluted 1:500) were used.151-153,212 
The staining observed in the lens fibers was considered to represent the background level 
of staining, and tumor areas which had a stronger immunoreaction than that were considered 
positive. Any cystic or necrotic parts of the tumor were excluded from the tumor area. The 
lens  epithelium and  non-pigmented  ciliary  epithelium,  which  are  known to  express  IGF-1R 
were used as internal positive controls in the immunohistochemical staining.213 
 
5.1.9 Assessment of Tumor-Infiltrating Macrophages 
 
MAb PG-M1 (IgG3; lot 101; Dakopatts; diluted 1:50) to the CD68 epitope, a 110-kDa 
glycoprotein of lysosomal granules expressed by macrophages in most human tissues, was 
used to identify tumor-infiltrating macrophages.203 The number of immunopositive cells was 
graded semiquantitatively by comparing CD68 immunostained sections to standard 
photographs (few vs. moderate vs. high number of cells).203 
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Summary of the antibodies used including dilutions and manufacturer information 
 
Antibody Clone/Lot Purpose of use Manufacturer Country Dilution 
Mouse 
monoclonal 
antibody (mAb) 
Ki-67 
Clone 7B11 
Lot 30276010C 
Cell proliferation 
assessment  
Zymed 
Laboratories 
San Francisco, 
CA, USA 
1:10 
Mouse 
monoclonal 
antibody (mAb) 
Ki-67 
Clone MIB-1 Lot 
012(201) 
Cell proliferation 
assessment 
DAKO A/S Glostrup, 
Denmark 
Different 
concentrations 
Mouse 
Monoclonal 
Anti-PCNA  
Clone PC10 
Lot 71K4870 
Cell proliferation 
assessment 
Sigma Chemical St. Louis, MO, 
USA 
Different 
concentrations 
Rabbit 
polyclonal 
antibody of IGF-
1R? 
N-20 
SC-712 
Tumorigenesis 
assessment 
Santa Cruz 
Biotechnology 
CA, USA 1:500 
Mouse 
monoclonal 
antibody (mAb) 
PG-M1 to CD68 
epitope 
IgG3 
Lot 101 
Macrophages 
assessment 
DAKO A/S Glostrup, 
Denmark 
1:50 
Mouse 
monoclonal 
antibody (mAb)  
to CD34 epitope 
cloneQBEND/10 
Lot 121202 
Microvessels 
assessment 
 
Novocastra 
Laboratories 
Newcastle-
upon-Tyne, UK 
1:25 
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6. STATISTICAL METHODS AND DATA ANALYSIS 
 
All analyses were performed with Stata® (ver. 7.0 -10.0; Stata Co, College Station, TX), 
and StatXact-3 (Cytel Co, Cambridge, MA) statistical software. 
Descriptive statistics for normally distributed variables are given as means and standard 
deviations and for other variables as medians and ranges.214 P < 0.05 was considered 
statistically significant. All tests were two-tailed. Median and range are given as descriptive 
statistics. 
 Kruskal-Wallis test was used to compare continuous variables between categories. 
Spearman’s rank correlation was used to analyze interrelationships between two continuous 
variables. The Wilcoxon signed-rank test or non-parametric test for trend was used to 
compare distributions of paired continuous data, and the Stuart-Maxwell test to compare 
unordered paired contingency tables, respectively.215 
Intraobserver agreement in measuring MLN was assessed by plotting the difference 
between the measurements against their mean and by calculating the mean difference with 
95% confidence limits.214 Interobserver reproducibility was similarly assessed.  
Overall survival was calculated as the time from the date of diagnosis of metastases to 
death.  Survival was analyzed with the Kaplan-Meier product-limit method and log-rank test. 
Survival was modeled using Cox proportional hazard regression.  
Univariate analyses of survival time data were based on the Kaplan- Meier product-limit 
method without taking competing risks into account.216 217 
 Patients  judged  to  have  died  from  causes  other  than  UM  were  censored.  Cell  type  and  
tumor location were dichotomized according to the presence of epithelioid cells (spindle, 
nonspindle)207 and ciliary body involvement (not involved, involved). Extravascular matrix 
loops and networks were coded as a three-category variable, considering networks to be an 
advanced stage of loops (no loops, loops without networks, networks).53 Largest basal tumor 
diameter (LBD) was coded in three categories (<10, >10–15, and >15 mm). MVD and MLN 
were divided in two or three categories according to their median and tertiles, respectively. 
Ki-67 immunoreactivity was analyzed in two (absent, present) or three categories (absent, 
lower than median, higher than median). 
Cox proportional hazards regression was used to adjust survival time data for the effect of 
other prognostic factors.216 LBD and MVD were modeled as continuous variables and MLN 
alternatively as divided in tertiles to assess robustness of results. MVD was square-root 
transformed to obtain normal distribution.30,134 Independent variables were allowed in the 
model if  P < 0.10, and different models were compared with the likelihood ratio test.217 The 
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number of variables was restricted to four; based on a rule to have at least 15 to 20 events for 
each additional variable.216 The  regression  coefficients  and  hazard  ratios  (HR)  with  95%  
confidence intervals (CI) were calculated. The assumption of proportional hazards was tested 
by the method of Therneau and Grambsch.218 
 LBD and MVD were modeled as continuous variables. MVD was square-root transformed 
to obtain normal distribution.30,134 Independent variables were allowed in the model if p < 
0.10, and different models were compared with the likelihood ratio test.217 The number of 
variables  was  restricted  to  four,  based  on  a  rule  to  have  at  least  15  to  20  events  per  each  
additional variable.216 The  assumption  of  proportional  hazards  was  tested  by  the  method  of  
Therneau and Grambsch.218 
For the analysis of MLN the minimum sample size was calculated on the basis of a 
previous consecutive series, which reported the cumulative 10-year probability of survival to 
be 0.69 and 0.22 for patients who had a melanoma in which MLN was lower and higher than 
the median respectively, corresponding to a survival difference of 0.476 Power analysis 
indicated that to detect a similar difference as significant with a power of 80%, the study 
should have a minimum of 58 patients (Power and Precision, ver. 2.0; Biostat, Englewood, 
NJ). The other studies were more exploratory in nature and were not based on calculations 
after previously published data.
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7. RESULTS  
 
7.1 Clinical and Histopathological Tumor Characteristics   
 
7.1.1 MLN in primary tumors   
 
Nucleoli were identified in 126 (75%) of the 167 slides (Figure 1A Paper I). The 
median MLN was 4.05 µm (range, 2.60–6.18), and the mean was 4.06 µm (SD 0.54), 
which was comparable with other studies.37-39,46,48 (Table 1; Paper I)  
The mean difference for reevaluating MLN using the Bland-Altman method for 
intraobserver comparison was +0.097 µm (95% CI, –0.025 to +0.22) (Figure 1B; Paper 
I), and the mean for interobserver comparison was –0.38 µm (95% CI, –0.51 to –0.25; 
Figure 1C; Paper I). The greater difference may be due to personal preference in caliper 
positioning. 
 
7.1.2 MLN in metastatic tumors and their corresponding primaries 
 
Nucleoli were identified in all 37 metastatic melanoma specimens, and in the 26 
corresponding primary tumor specimens using the silver staining method. The median 
MLN in the matched primary UM was 4.1 µm (range, 3.3–5.2), and the mean was 4.2 µm 
(SD 0.52) (Table 1; Paper III). 
The specimens of metastases fell into three subcategories, specimens from surgical 
biopsies (12), specimens from autopsies (24), and a specimen from a core needle biopsy 
(1). (Table 1) The median MLN in the surgical biopsies was 3.9 µm (range 3.2– 6.4), and 
the mean was 4.3 µm (SD 1.14), in the autopsy specimens the median was 3.5 µm (range 
2.7– 5.7) and the mean 3.7 µm (SD 0.72) (Figure 1B; Paper III). The MLN in the single 
core needle biopsy was 3.8 µm. In the autopsy specimens MLN values were smaller in 
comparison to the surgical specimens (P = 0.065, Kruskal–Wallis test). (Table 1) 
In the metastatic group of autopsied patients, three patients had received either 
chemotherapy or irradiation for their metastases while 12 did not receive any treatment. 
In the treated group the mean MLN was 3.6 µm and for those who did not receive any 
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treatment the mean was 3.9 µm, although the median MLN for both groups was 3.6 µm. 
(Table 1). 
The MLN in the autopsy group had a trend towards a smaller median value, which 
could be due to a post mortem artifact. To clarify this, the MLN was measured from 
normal hepatocytes in liver tissue available in two surgical and four autopsy specimens 
and compared. The median MLN was 2.2 µm in the surgical specimen, and 2.7 µm in the 
autopsy specimen, indicating that smaller MLN in metastases was not likely to be a 
systematic post mortem artifact. 
Generally, hepatic metastases in all types of specimens combined had a smaller MLN 
than the corresponding primary UM, the median MLN was 3.6 µm (range 2.7–6.3) and 
mean 3.9 µm (SD 0.91), the mean difference between pairs being 0.55 µm ( P = 0.066, 
Wilcoxon signed rank test) (Figure1 C; Paper III). 
 
TABLE 1. Comparison of MLN measured from different specimens of hepatic metastases  
------------------------------------------------------------------------------------------------------------ 
      Hepatic metastasis 
      (n=37)     
 
 
     Surgical biopsies   Autopsy       Needle biopsy 
Characteristic   (n=12)   (n=24)         (n=1)  
------------------------------------------------------------------------------------------------------------ 
Median MLN, (range) 3.9 (3.2– 6.4) 3.5 (2.7– 5.7)              3.8† 
 
Mean MLN (SD)  4.3 (1.14)  3.7 (0.72)                    3.8† 
Median MLN of hepatocytes  2.2  2.7  -  
Treatment given                               - 3.6  -  
No treatment                                    - 3.9                                - 
------------------------------------------------------------------------------------------------------------ 
† Single specimen
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7.1.3 Microvascular factors in primary tumors  
 
MVD was identified in 113 (68%) of the 167 slides. The median MVD was 32 
counts/0.313 mm² (range, 5–121), and the mean was 37 counts/0.313 mm² (SD 23). Likewise 
extravascular matrix patterns were identified from 115 (69%) of the 167 slides. They were 
divided into three groups: no loops (40%), loops only (23%), and networks (37%).  
 
7.1.4 Microvascular factors in metastatic and matched primary tumors 
 
MVD was identified from 37 metastatic UM, and from 36 of the 37 corresponding primary 
tumors  (Table  1;  Paper  III).  The  median  of  MVD  in  the  matched  primary  UM  was  44.5  
counts/0.313 mm². In the metastatic specimens, MVD was 56 counts/0.313 mm², which was 
significantly higher than in the primaries (median difference, 7.5 counts/0.313 mm² more, 
range 38 counts less to 70 counts more; P = 0.044, Wilcoxon signed rank test) (Figure 1E; 
Paper III). MVD in metastases was not associated with specimen diameter (P = 0.62, 
Spearman’s rank correlation) (Figure 1F; Paper III), which was thus unlikely to be a 
confounding factor. 
 
7.1.5 Ki-67 Immunopositivity in primary tumors 
 
The tumor cross-sectional area was successfully measured from 137 (82%) of the 167 
slides. Its median was 29 mm² (range, 1.2–135). The nuclei were successfully identified and 
counted in 141 (84%) of the slides. The median number of cells was 1,655 cells/mm² (range, 
315–5,554), based on the number of nuclei identified.  
Immunostaining of tumor slides with mAb Ki-67 was successful in 141 (84%) of the 167 
slides (Figures 1C and D; Paper II). The median number of immunopositive Ki-67 cells was 8 
per tumor cross-section (range, 0–272) and the mean was 32 cells (SD, 50), corresponding to 
a median of 0.30 cells/mm² (range, 0–53) and a mean of 1.7 cells/mm² (SD 5.2). The median 
percentage of Ki-67 immunopositive cells of all cells identified (proliferation index) was 
0.02% (range 0–3.2) and the mean was 0.1% (SD 0.3). 
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7.1.6 IGF-1R Immunopositivity in primary tumors 
 
The tumor was successfully measured from 129 (78%) of the 166 slides of primary UM. 
Immunoreactivity for IGF-1R varied from cell to cell and between tumor areas. The median 
tumor area was 34 mm² (range, 2-145). The median percentage of tumor area that was graded 
as immunopositive was 68% (range, 0-100) and its mean was 60% (SD, 39). Of the 129 
tumors, 21 did not stain for IGF-1R. 
 
7.2 Interrelationships between prognostic indicators  
 
7.2.1 MLN in primary tumors 
 
When epithelioid cells existed in the tumor, MLN was greater than if it consisted of spindle 
cells only (difference, 0.31 µm; P = 0.017, Kruskal-Wallis test; Figure 2A Paper I), MLN also 
rose with rising MVD (P = 0.0053, Spearman’s correlation; Figure 2B Paper I). MLN was not 
associated with gender (P = 0.21, Kruskal-Wallis test), ciliary body involvement (P = 0.44, 
Kruskal-Wallis  test),  LBD  (P = 0.24, nonparametric test for trend; Figure 2C Paper I), 
pigmentation of the tumor (P = 0.84), presence of tumor-infiltrating macrophages (P = 0.78), 
and extravascular matrix loops and networks (P = 0.62; Figure 2D; Table 2; Paper I). 
 
7.2.2 Ki-67 Immunopositivity in primary tumors 
 
When the tumor type was non-spindle, the percentage of Ki-67 immunopositivity was 
higher than if the tumor consisted exclusively of spindle cells (median, 0.028% vs. 0%; P = 
0.089 Kruskal-Wallis test). Proliferation index plot against tumor cross-sectional area 
suggested that this index is smaller in larger tumors (Figure 2B; Paper II). No similarities 
were seen between Ki-67 immunopositivity and gender, ciliary body involvement, LBD, 
pigmentation of the tumor, presence of tumor-infiltrating macrophages, MLN (Figure 2C; 
Paper; II), MVD, and the presence of extravascular matrix loops and networks (Table 1; Paper 
II). 
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7.2.3 IGF-1R Immunopositivity in primary tumors 
 
High  MVD  appeared  to  be  associated  with  the  percentage  of  the  tumor  area  which  was  
immunopositive for IGF-R1 (P = 0.060) (Table 1; Paper IV). Heavy pigmentation and greater 
number of macrophages were also associated with the percentage of tumor area which was 
immunopositive (P = 0.001 and P = 0.003 respectively). Extrasclerally extending tumors had 
small proportion of immunopositivity for IGF-1R (P = 0.049). (Table 1; Paper IV). 
No significant  association  was  found between the  proportion  with  IGF-1R positivity  and  
involvement of the ciliary body, LBD, MLN, cell type, and extravascular matrix patterns 
(Table 1; Paper IV).  
 
 
7.3 Melanoma-specific Mortality  
 
7.3.1 Survival Outcome 
 
In the study of MLN in primary tumors (Paper I), 21% of 126 patients were alive at the end 
of follow-up, 48% had died of metastatic UM, 6% had died of second cancer confirmed by 
histopathology, 25% had died of other diseases not related to malignancy, and one had died of 
unknown causes (Table 2). 
Regarding Ki-67 in primary tumors (Paper II), 20% of 128 patients were still alive at the 
end of follow-up, 52% had died of metastatic UM, 5% of a second cancer confirmed by 
histopathology, 23% of unrelated disease, and one patient had died of unknown causes (Table 
2). 
For  the  IGF-1R  study  in  primary  melanomas  (Paper  IV),  17%  of  129  patients  were  still  
alive  by  the  end  of  the  follow-up,  50% had  died  of  metastatic  UM,  6% of  a  second cancer  
confirmed by histopathology, and 27% had died of other causes (Table 2). 
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TABLE 2. Survival outcome of the patients included in the three studies of primary UM 
-----------------------------------------------------------------------------------------------------------------     
 MLN Ki-67   IGF-1R 
Survival outcome (n=126) (n=128)   (n=129) 
----------------------------------------------------------------------------------------------------------------- 
Patients still alive 26 (21%) 26(20%)  22 (17%)   
UM metastatic death 60 (48%) 66 (52%) 64 (50%) 
Second cancer death   8 (6%)   6 (5%)    8 (6%) 
Other cause of death 31 (25%)     29 (23%) 35 (27%) 
Unknown cause of death   1   1      -  
----------------------------------------------------------------------------------------------------------------- 
 
7.3.2 Prognostic significance of MLN, Ki-67, and IGF-1R by Kaplan-Meier analysis 
 
Melanoma-related mortality was associated with LBD (P = 0.0007 log-rank test for trend; 
Figure 3C Paper I, and P = 0.0065 Table II Paper II respectively), presence of epithelioid cells 
(P = 0.0001 log-rank test; Figure 3D Paper I, and P < 0.0001 Table II; Paper II respectively). 
As analyzed in the Ki-67 study, melanoma-related mortality was also associated with ciliary 
body involvement (P = 0.0065), degree of tumor pigmentation (P = 0.0067), presence of 
tumor-infiltrating macrophages (P = 0.013) and MLN (P = 0.06) by Kaplan-Meier analysis 
(Table 2; Paper II). 
Likewise, melanoma-related mortality was associated with microvascular loops and 
networks  (P = 0.0001 log-rank test for trend; Figure 3E Paper I, and P = 0.0001 Table II; 
Paper II respectively), and MVD (P =0.0001 log-rank test for trend; Figure 3F Paper I, and 
P<0.0001 Table II; Paper II respectively).  
The Kaplan-Meier estimate for 10-year survival was 0.80 (95% CI, 0.64–0.90) if no loops, 
0.48 (95% CI, 0.27–0.67) if loops were present without networks, and 0.40 (95% CI, 0.25–
0.55) if loops forming networks were present (Paper I). The corresponding estimates 
according to tertiles of MVD were 0.86 (95% CI, 0.70–0.94), 0.50 (95% CI, 0.33–0.65), and 
0.41 (95% CI, 0.24 0.57) respectively. 
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Melanoma-related mortality rates were significantly associated with MLN (P = 0.0060, 
log-rank test for trend; Figure 3A, Paper I). The 10-year Kaplan-Meier estimate for survival 
was 0.74 (95% CI, 0.56–0.85) for small, 0.60 (95% CI, 0.44–0.74) for medium, and 0.42 
(95% CI, 0.25–0.58) for large MLN.  
When Ki-67 immunopositive cells were present, the melanoma-related mortality was 
statistically higher than if they were absent (P = 0.050, log-rank test; Figure 3A; Paper II). 
The 10-year Kaplan-Meier estimate of mortality was 0.38 (95% CI, 0.26–0.52) for tumors 
which did not include Ki-67 immunopositive cells, and 0.50 (95% CI, 0.38–0.73) for tumors 
that contained Ki-67 immunopositive cells. 
The Kaplan-Meier estimate for melanoma-related mortality was comparable, however, for 
both immunopositive groups when divided into three categories according to the median 
number of Ki-67 immunopositive cells (first category was negative for Ki-67, second was 
below the median, and the third was above the median). (P = 0.80, log-rank test; Figure 3B; 
Paper II).  
Melanoma-related mortality was not associated with the area of IGF-1R immunopositivity 
by Kaplan-Meier analysis when divided in four categories (P = 0.832), (Table 2; Paper II).  
 
7.3.3 Prognostic significance of MLN in metastatic tumors 
 
Overall survival rates between patients having metastasis with a smaller versus larger 
MLN than the median value were comparable (1.1 months versus 1.8 months; P = 0.95, log-
rank test) (Figure 2A; Paper III). Overall survival was longer if the metastases had a smaller 
MVD value than the median (6.5 months versus 1.5 months; P = 0.096, log-rank test) (Figure 
2B; Paper III). 
 
 
7.4 Cox Proportional Hazard Regression Analyses of MLN, Ki-67, and IGF-1R in 
Primary Tumors 
 
7.4.1 Univariate analysis  
 
MLN was significantly associated with melanoma-related mortality as a continuous 
variable (P = 0.016; HR = 1.82 for each micrometer increase), and was also significant as a 
categorical variable (P = 0.007; HR = 1.57 for each category increase). (Paper I)  
Results  
 44 
Ki-67 immunoreactivity was associated with melanoma-related mortality (P = 0.052; HR = 
1.65 for tumors with immunopositive cells).  
By Cox regression analysis, tumor area immunopositive for IGF-1R was not associated 
with survival in univariate analysis (HR 1.01 for each 10 percentage point increase in 
immunopositive tumor area; 95% CI 0.95-1.08, P = 0.70). 
Other variables associated with melanoma-related mortality were ciliary body involvement 
(P = 0.003; HR = 2.34 in Paper I, P = 0.008; HR = 2.04 in Paper II), large LBD (P = 0.001; 
HR = 1.13 in Paper I, P < 0.001; HR = 2.55 in Paper II ), presence of epithelioid cells (P = < 
0.001; HR = 2.28 in Paper I, P < 0.001; HR = 3.22 in Paper II), grade of pigmentation (P = 
0.017; HR = 1.54 in Paper I) presence of microvascular loops and networks (P < 0.001; HR = 
1.80 in Paper I , P < 0.001; HR = 1.72 in Paper II) and high MVD (P = <0.001; HR = 1.80 in 
Paper I , P <  0.001;  HR  =  1.30  in  Paper  II)  (Table  3,  Paper  I;  and  Table  2,  Paper  II  
respectively). 
 
7.4.2 Multivariate analysis  
 
The bivariate and multivariate models showed that MLN was a significant predictor of 
prognosis, both as continuous and categorical variable, when adjusted for the effect of ciliary 
body involvement, LBD, presence of epithelioid cells, and microvascular loops and networks 
(Table  3;  Paper  I).  MLN  was  of  borderline  significance  when  adjusted  as  a  continuous  
variable for MVD (P = 0.11) (Table 3; Paper I).  
Of all the bivariate models tested, two models which linked MLN with cell type and MLN 
with MVD predicted best melanoma-specific survival, and of these two, the one which 
included MVD was the best predictor (Table 3; Paper I). The other model linking MLN with 
microvascular loops and networks was better than the models linking MLN with ciliary body 
involvement, and MLN with LBD. When the four best predictors were combined in 
multivariate models, MLN lost its statistical significance when modeled as a continuous 
variable (P = 0.11–0.18) but retained its significance as a categorical one (P = 0.023–0.067) 
(Table 3; Paper I). 
Ki-67 immunopositive cells remained an independent predictor of prognosis when adjusted 
in turn for the effect of MLN and MVD in bivariate models (Table 2; Paper II). The models 
which combined Ki-67 immunoreactivity with cell type and MLN best predicted melanoma-
related mortality among all six models tested (models 3 & 4; Table 2; Paper II), and of these 
Results  
 45 
two models number three was the preferred one (Table 2; Paper II; -2 log likelihood = 482.7 
vs. 526.5; difference, 43.8; P < 0.0001 ?² test). 
When Ki-67 immunopositivity and MLN were combined with presence of epithelioid cells 
(model  7  Table  2;  Paper  II),  extravascular  patterns  (model  8  Table  2;  Paper  II),  and  MVD  
(model 9 Table 2; Paper II), the fit improved, and the model with cell type provided the best 
fit (-2 log likelihood = 447.9 vs. 460.5; difference, 12.6; P = 0.0004). Ki-67 immunopositivity 
and MLN decreased in significance in a model with four variables (Table 2; Paper II), but the 
general model fit improved (?2 log likelihood = 434.9 vs. 447.9; difference, 12.4; P = 
0.0004). 
IGF-1R immunoreactivity was not an independent predictor of prognosis when including 
IGF-1R tumor area and MLN in a bivariate model (-2 log likelihood = 446.5, P = 0.937; 
Model 1; Table 3). The same applies to a bivariate model which included IGF-1R tumor area 
and MVD (-2 log likelihood = 447.8, P = 0.86; Model 2; Table 3). Nor did IGF-1R predict the 
prognosis in a trivariate model which combined IGF-1R immunopositive tumor area, MLN, 
and MVD (-2 log likelihood = 414.0, P = 0.44; Model 3; Table3). 
TABLE 3. Multivariate model of IGF-1R immunoreactivity and melanoma-related mortality of patients with UM 
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 
                      IGF-1R immunoreactivity modeled as a categorical variable 
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 
   Regression                  Wald                                                      Hazard ratio  
   Coefficient (SE)                 chi-square           P                          (95% CI)  
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 
BIVARIATE ANALYSIS 
  Model 1, -2 log likelihood = 446.5   
IGF-1R area*   0.003 (0.038)     0.006  0.937  1.00 (0.93-1.08)  
MLN†   0.545 (0.298)    3.35  0.067  1.72 (0.97-3.09) 
  
    Model 2, -2 log likelihood = 447.8   
 IGF-1R area*   -0.006 (0.037)   0.029                                   0.865  0.99 (0.92-1.07)  
MVD ‡   0.319 (0.077)   17.057  0.000  1.37 (1.18-1.60)  
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MULTIVARIATE ANALYSIS 
  Model 3, -2 log likelihood = 414.0 
IGF-1R area* _0.031 (0.409)  0.592                                  0.441  0.97 (0.89.-1.05) 
MLN† 0.414 (0.311)  1.769  0.184  1.51 (0.82-2.79) 
MVD‡ 0.299 (0.083)  13.032  0.000  1.35 (1.15-1.59) 
-------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 
 
SE = standard error 
CI = confidence interval 
* Continuous variable, 10 percentage points  
 † Coding: First tertile = 0, Second tertile =1, Third tertile= 2  
 ‡ Continuous variable, square–root transformed vessel count/0.313mm2  
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8. DISCUSSION 
 
8.1. Strengths and Limitations of the Study 
 
There  are  some  limitations  in  this  study,  mainly  as  some  of  the  specimens  were  not  
satisfactory due to technical reasons. For example, it was technically difficult to evaluate the 
tumor  area  in  some  specimens  due  to  loss  of  tissue,  folds,  or  artifacts.  On  the  other  hand,  
some tumors were very small (to evaluate), or simply necrotic. In some heavily pigmented 
tumors it was difficult to identify the nucleoli or the immunoreaction despite bleaching of 
melanin.  
As mentioned, specimens may lose some immunoreactivity during the laboratory process; 
e.g. because of formalin-induced cross-linking; and sometimes the intensity of retrieved 
immunoreactivity might vary from batch to batch. In addition, it was sometimes difficult to 
distinguish the borderline of true immunopositivity from the background, despite the use of 
positive controls. 
Therefore, future projects using fresh UM material should be considered, to rule out the 
possibility of technical issues related to formalin-fixed, paraffin-embedded material. Because 
of the rarity of UM, this likely will necessitate prospectively collected, collaborative tissue 
banks.  
The strength of this study resides in the fact that it is a consecutive, population-based 
cohort study, with good quality survival data and a long follow-up time. All the 167 malignant 
UM patients who had an eye enucleated because of choroidal and ciliary body melanoma 
were verified from the records of the ophthalmic pathology laboratory, Helsinki University 
Central Hospital, the main referral center which manages almost all uveal melanomas in 
Finland. 
Cause of death was validated by reviewing all patient records relating to malignant tumors 
and death, crosschecking with the Finnish Population and Cancer Registries, and by acquiring 
all histopathological material available from primary tumors, metastases, and second cancers 
during this and earlier studies undertaken in this research laboratory.30,53,136 
 
8.2 Main findings and their implications  
 
A main goal of this dissertation was to study MLN, and microvascular factors in primary 
UM and their association with metastasis using a population-based retrospective cohort data 
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set, and to evaluate whether these factors are independent predictors of survival in primary 
UM. Additionally, the association of cell proliferation in the same data set was evaluated by 
using the Ki-67 antibody in conjugation with MLN and other prognostic factors. Finally, the 
association between immunoreactivity for IGF-1R in primary UM and metastatic death was 
investigated, because proliferation of tumor cells in vitro can be reduced with substances 
which inhibit this receptor.153 
The mean MLN in primary UM was greater than previously published figures (Table 1; 
Paper I).37-39,46,48 This difference between studies could be multifactorial. One possibility is 
the effect of the staining substance. Silver was used in this study, and this is known to display 
nucleoli as larger than HE, thereby causing a difference in size.48 Because silver staining 
defines the boundaries of the nucleolus  sharper than in HE staining, it facilitates the detection 
of irregularly shaped nucleoli allowing accurate discrimination of nucleoli.42,48 One study 
found that measurements from silver stained slides were easier to make and provided better 
prognosis than those from hematoxylin-eosin slides.48 
Another factor is the method used for measurement, because MLN will be smaller if the 
horizontal diameter of the nucleoli is measured instead of their longest diameter.46 Sampling 
techniques may well explain part of the difference in MLN between various studies. In the 
present study the sample was taken from the central 5-mm of the tumor, rather than from the 
whole tumor area,  which has also been reported in another study  to result  in a larger MLN 
mean value.48 
Given the association between death and MLN in UM,33,36-38,41,46,48 selecting the data may 
have affected the MLN mean values. Earlier studies selected the patients in two groups, the 
first group containing half of the patients who died because of metastatic UM, while the other 
half had survived for a minimum of 10 years without any evidence of metastasis.33,35,38,48  
As these studies excluded patients surviving for a short time and possibly still at risk for 
developing metastasis, the mean MLN could have been biased towards a smaller value, as 
these patients were excluded from the analysis while they were still at risk of developing 
metastatic disease. Lastly, interobserver measurement variations may contribute to difference 
in mean MLN, as reported39 and as also was the case in my study. 
In the present study MLN was strongly associated with death from UM, and the 10-year 
cumulative proportion for those who died was 0.32 units larger if the patients had UM with a 
large rather than a small MLN. Likewise, the risk of death was 3.1 times higher by Cox 
regression analysis if UM had a large MLN. One study reported the 10-year survival 
difference as 0.47,37 which is broadly comparable with my result. 
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MLN was significantly larger in UM which contained epithelioid cells,46,48 but no 
significant difference in MLN was found according to ciliary body involvement,46 and the 
presence of extravascular matrix loops and networks.39,46 MLN in this study was not 
associated with LBD as reported in other studies.39,46,48 Adding a new discovery, not reported 
earlier this study suggests that  MLN is significantly associated with MVD. 
 In spite of the connection between MLN and the presence of epithelioid cells, both 
independently predicted survival by bivariate Cox regression, confirming some36 but  not  all  
previous analyses.33 Additionally, the fit of this model to the data was significantly better than 
that of competing models including ciliary body involvement, LBD, and microvascular loops 
and networks. The findings that MLN maintain significance when adjusting for LBD,33,35,36 
loops,41 and networks46 concurs  with  earlier  multivariate  studies.  It  is  appropriately  well  
established that MLN and microvascular loops and networks in UM are unrelated, but other 
microvascular patterns have not been evaluated in this regard. 
 
MVD is likewise known to be an important prognostic factor in UM, independent of 
extravascular matrix loops and networks.30,59,134 The association of MVD with prognosis may 
reflect the aggressiveness of UM tumor cells which either promote angiogenesis or share 
features with endothelial cells.59 It was found that multivariate models which included MVD 
and MLN fitted better with survival than models which had excluded MVD.  
Given that MLN and extravascular matrix patterns predict the prognosis in UM may be in 
line with the theory that they could represent different stages possibly related to the metastatic 
capability, such as their ability to metastasize and proliferate. Along with their ability to 
express the degree of malignancy in melanoma cells,117 extravascular matrix loops and 
networks and hot spots which correlate to high MVD harbor the vascular channels, which 
may be involved when the UM cells pass through the blood circulation. One could speculate 
that nucleolar size is connected to tumor growth, as high metabolism is connected to active 
transcription, translation and gene activation. The possibility to send metastases and to 
proliferate is probably interrelated;219 it was observed in this study that MVD illustrates some 
prognostic association with MLN, and because UM cells express some antigens occasionally, 
which can be measured based on MVD,59 future investigations of nucleoli in UM which share 
these antigens might reveal a relationship at the cellular level.  
 To  sum  up,  in  this  data  set  it  was  not  only  proven  that  MLN  and  extravascular  matrix  
loops and networks  are  independent  predictors of survival in UM,41,46 but it was also found 
that adding MVD to multivariate models with MLN fitted better with survival.  
Discussion 
 51 
 In addition to studying nucleolar size and microvascular factors in primary UM, this study 
investigated these factors in corresponding hepatic metastases. Generally the median MLN 
turned out to be smaller than in the corresponding primary tumors; whereas the opposite was 
true for MVD, which was larger in the metastases than in corresponding primary tumors.  
Another interesting finding was that the MLN values from the autopsy specimens tended to 
be smaller than those of surgical biopsies. This was initially thought to be due to post mortem 
changes or artifacts. To verify this, MLN was measured from hepatocytes in normal liver 
tissue and the same groups of specimens were compared, but no difference was found. Thus, 
the  difference  was  not  likely  to  be  due  to  post  mortem artifacts.  In  spite  of  the  mean MLN 
being smaller in metastases, MLN in certain metastases was nevertheless larger than in the 
corresponding primary UM, another possibility might be that most of the sampled metastases 
showed a minority which were dormant, hence the smaller nucleoli.   
The median MVD in the primary tumors was lower than in the corresponding hepatic 
metastases. The MVD in the metastasis was not associated with specimen diameter; although 
the smaller the specimen is the more likely it is that such a sample does not represent the “hot 
spot” of densest microvascularization in the biopsied metastasis.  
MVD is a well known prognostic indicator associated with shorter survival after diagnosis 
of primary UM.30,58,59 In  the  primary  UM,  MVD  may  indicate  tumor  angiogenesis  and  
aggressiveness. High MVD in the primary UM is associated with the presence of epithelioid 
cells,30 which turned out to be true for the matched metastasis as well.  
In line with the fact that the presence of high MVD in primary UM is associated with a 
shorter time for developing metastases than the presence of low MVD,30,58,59 high MVD in 
metastasis was associated with short survival after diagnosis of metastasis.203  
Once hepatic metastases were diagnosed, the survival was similar regardless of high or low 
MLN in the metastases, and therefore MLN in metastasis was not a prognostic indicator of 
survival.  
Folberg et al. suggested that because no current effective treatments are available for 
metastatic UM, modeling the behavior of UM in the liver is important in order to study the 
biology of metastatic disease and to treat future metastasis.220  
Many cell proliferation markers are available commercially, such as PC-10, and Ki-67. Ki-
67 recognizes a nuclear antigen present in proliferating cells, but does not detect cells in 
resting phase.143 Ki-67 has been studied by several authors as a tool to detect proliferating 
cells in UM.49,221-223 Some of the factors known to be associated with Ki-67 immunopositivity 
include p53 expression, larger tumor size, and shorter survival.145,224,225 
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PC-10 on the other hand is a cell cycling marker,226 and  has  been  studied  for  its  role  in  
evaluating cell proliferation in UM,50,51,226 but it failed to work reliably with my paraffin 
sections,  therefore  Ki-67  was  used  as  my  primary  antibody  to  study  the  association  of  cell  
proliferation in UM with MLN, microvascular factors, and survival.  
In the present study the median Ki-67 proliferation index was 0.02% (range, 0.7% - 1.7%) 
and less than in some published reports49,211,222,223,227 (Table  3;  Paper  II).  The  percentage  of  
immunopositive tumors was also lower, 56% versus 87% -100% in other studies.49,52,211,222-
225,227 
A significant overlap was observed among the ranges in the published papers (Table3; 
Paper II).49,211,222-224 52,225,227 A considerable number of factors could affect the median 
proliferation index. In this study the whole tumor area was evaluated for nuclear 
immunopositivity, while some authors have calculated the proliferation from random areas of 
the tumor 211,223,227 or tumor “hot spots”.52,224 The latter method obviously might explain the 
higher mitotic index obtained (Table 3; Paper II).  
Another factor worth considering is the counting methodology (Table3; Paper II). The 
percentage of immunopositive cells was calculated in this study relative to all cells in the 
tumor, while others have calculated the fraction of immunopositive cells relative to cells 
counted from 10 to 20 high power fields (HPF).49,211,222,223,227 Some authors have simply 
counted immunopositive cells within an HPF irrespective of differences in the total number of 
cells in these fields.52,224,225 The present study showed that proliferation estimated by two 
methods from the same tumors may result in different conclusions. 
Proliferation index values may also be affected by factors related to specimen processing; 
for example the specimen may lose its immunoreactivity during the staining process due to 
formalin-induced cross-linking, but this can be overcome by using antigen retrieval methods, 
such as heat treatment. These, however, often differ across laboratories (Table 3; Paper II). 
The  effectiveness  of  reagents  may  vary  depending  on  the  batch  used.  Use  of  controls  may  
contribute to the interpretation of true immunopositivity as well; in some studies, only  
negative controls have been used,52,211,223-225,227 which may cause uncertainty in interpreting 
the immunoreactivity. Lymphoma tissue was used as a positive control in this study, because 
it had large numbers of immunopositive cells and helped differentiate true Ki-67 
immunopositivity  from  the  background.  Moreover,  in  some  specimens  when  the  tumor  cell  
nuclei were not immunopositive for Ki-67, the limbal epithelial served as an internal positive 
control.  
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The presence of epithelioid cells was associated with high proliferation index in the present 
study, as indeed in earlier reports,222,223 an observation which is in line with the fact that the 
presence of epithelioid cells is clinically associated with shorter tumor doubling times.114,228 
However, another study which had used the “hot-spot” sampling method reported an absence 
of any relationship with proliferation index and cell type.52  
In the present study, extravascular matrix loops and networks and Ki-67 immunopositivity 
were interrelated, similar to previous studies.224,225 This would support the hypothesis that  the 
presence of extravascular matrix patterns is evidence of the aggressiveness of UM cells.117 
Likewise Ki-67 proliferation index and ciliary body involvement were interrelated, which was 
also noted in another study.222 Ciliary body melanomas indeed metastasize more often than 
choroidal tumors which do not involve the ciliary body. 
Differences between the studies mentioned in noticing the associations above may be due 
to the generally small number of specimens studied, and the variations in counting the 
proliferation index with Ki-67 antibodies which, as mentioned, are subject to differences in 
tissue processing techniques between different laboratories. Results from larger studies,52,222-
224 such as the present one, must still be analyzed and further studies are needed to resolve the 
remaining discrepancies  by staining more specimens from different laboratories. 
The association of Ki-67 immunopositivity with the survival of patients with UM has not 
been studied earlier. Previous work has generally addressed the proliferation index after 
irradiation.49,52,211,223,225,227 In this study, a proliferation index higher than zero corresponded 
to 1.6 times higher mortality than absence of Ki-67 immunopositivity. 
Ki-67 immunopositivity fitted best with the survival data when combined with MLN and 
the presence of epithelioid cells, and both remained independent indicators of high metastatic 
risk. In contrast, Ki-67 immunopositivity was not clearly connected with MVD or the 
presence of extravascular matrix loops and networks.  
Cell proliferation index has been evaluated earlier by using other proliferation markers 
(such as PCNA), and a high index has been associated with shorter survival in patients with 
UM.46 Proliferation index, LBD, MLN, and extravascular matrix loops and networks were 
independent predictors of melanoma-related mortality in that study, whereas the cell type was 
not.46 Unfortunately, PCNA failed to work properly in my hands. These findings taken 
together nevertheless support the hypothesis that a high cell proliferation index is associated 
with a high risk of metastasis independent of MLN and extravascular matrix loops and 
networks. 
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Primary UM can now be divided into two classes based on the gene expression profile, in 
class 1 the tumor rarely metastasizes, whereas in class 2 there is a high risk for 
metastasis.94,229-231 Regarding the association between Ki-67 and gene expression profile, a 
recently published study232 reported a significant association between higher Ki-67 
immunopositivity and class 2 tumors compared to class 1 tumors. This study may explain why 
class 2 tumors have strong tendency to rapid metastasis, and it also independently confirmed 
that Ki-67 positivity is strongly associated with metastatic risk.232 
Liver is the main target for metastasis in UM, therefore some growth factors are thought to 
be produced there; of which the insulin-like growth factor-1 (IGF-1) and its receptor (IGF-1R) 
are important.149,150 It is thought as well that IGF-1R is involved in tumorigenesis,150,151 and 
may have a role in metastasis in malignant tumors.152  
In my study of prognostic associations of IGF-R in primary UM, the percentage of tumors 
immunopositive for IGF-1R was 84%, which was comparable to findings of other studies 
153,212 (76%-95%). These studies were based on 36 and 132 surgically removed melanomas 
respectively.153,212 In another study of 40 enucleated UM specimens varying in size from 
medium to large immunopositivity was found in only 20%.152 
Obvious variations were noticed among all these studies regarding their methods, the only 
common factor between them being use of the same primary antibody.  
In this study, the immunopositive tumor area was considered to be that which stained 
stronger than the background seen in lens fibers. Other studies have used the percentage of 
immunopositive cells instead, regardless of staining intensity.153,212 In  another  study,  tumor  
grading  was  not  based  on  the  presence  or  absence  of  cytoplasmic  immunopositivity,  but  on  
the presence of membranous immunostaining only.152 
Another factor is the loss of immunoreactivity due to formalin induced cross-linking, 
which was discussed earlier in this chapter (Chapter 8.2). One laboratory treated the slides 
with microwaves or digested them with pronase,153 whereas  in  another  study  there  was  no  
mention of antigen retrieval.212 A third study used microwaves and a citrate buffer.152 In our 
research laboratory, water bath treatment at 95ºC in a citrate buffer has been the preferred 
method as it often preserves ocular tissues better than cooking with microwaves because it 
does not involve boiling. 
After immunostaining, melanin was bleached because sometimes the granules could 
interfere with recognition of immunoreaction.206 This step has also varied between studies, 
and no bleaching of melanin was mentioned in one study,153 whereas in another bleaching was 
done with hydrogen peroxide and disodium hydrogen phosphate212 before immunostaining, 
Discussion 
 55 
which could have altered the immunoreactivity.206 Bleaching before immunostaining could 
well have caused the low percentage of immunopositivity in another study.152 
None of the published studies reported any relationship between ciliary body involvement 
or tumor size and IGF-1R immunoreactivity (Table 2; Paper IV). In one study, higher IGF-1R 
immunopositivity was seen in tumors which contained epithelioid rather than spindle cells   
(P = 0.046).153 
Darkly pigmented tumors were more frequently immunopositive than lightly pigmented 
ones in some studies (Table 2; Paper IV).152  Additionally it was noted that larger numbers of 
macrophages and a higher MVD were associated with larger IGF-1R immunopositive tumor 
areas. These factors have not been studied earlier. An association with heavy lymphocyte 
infiltration was, however, observed previously (P =  0.039,  Fisher’s  exact  test),  which   was  
able to be calculated from data in the study of Topcu-Yilmaz et al.152 (Table 1; Paper IV)  
Mäkitie et al. found that heavy pigmentation, larger numbers macrophages and high MVD 
were associated with one another.136 On the other hand macrophages and MVD, extravascular 
matrix loops and networks were not associated with IGF-1R. Nor did these patterns show any 
association with the number of macrophages,136 but they were associated with high MVD.30 
Taken together, the findings connect IGF-1R immunoreactivity more with presence 
macrophages than microvascular factors. 
All-Ericsson et  al.153 proposed that higher IGF-1R expression was associated with shorter 
survival rates, the 10-year rates of metastasis were reported as 33% vs. 71% for low vs. high 
expression153 respectively. This conclusion could be biased, as the study was exploratory. In a 
later study they reported a smaller survival difference, 30% vs. 44% vs. 59% for no vs. low 
vs. moderate to high expression respectively,154 but it  was not possible to prove such a large 
difference in my study. 
Future collaboration using fresh tumor material to avoid using formalin-induced cross-
linking from paraffin-embedded blocks should be considered to reassess the role of IGF-1R in 
predicting survival in UM before discarding this factor now because of contradictory results, 
because cyclolignan picropodophyllin inhibits the growth of UM both in cell culture and in 
xenografts.155,233 and could be applicable clinically. Taking all these factors together, 
however, assessing IGF-1R immunopositivity from formalin-fixed, paraffin-embedded 
material is not a practical method.  
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9. SUMMARY AND FUTURE DIRECTIONS 
 
 UM in general is a rare cancer, but it has the ability to metastasize hematogenously and 
shorten survival.24 The course of UM is poorly understood.234,235  It is well known that tumor 
size, location, and extrascleral extension are valuable clinical prognostic factors for 
diminished survival from UM.236 This study was undertaken to help to understand some 
histopathological factors which might contribute to developing metastasis in UM patients. 
Factors which could be related to tumor progression to metastasis disease, namely nucleolar 
size, MLN, MVD, cell proliferation, and IGF-1R were investigated. 
Of  the  167  patients  with  UM,  who  developed  metastasis  even  after  a  very  long  time  
following removal of the eye, metastatic disease was the main cause of death, as documented 
in the Finnish Cancer Registry and on death certificates. 
Using an independent population-based data set, it was confirmed that MLN and 
extravascular matrix loops and networks were unrelated, independent predictors of survival in 
UM.41,46 Also, it has been found that multivariate models including MVD in addition to MLN 
fitted significantly better with survival data than models which excluded MVD. This supports 
the idea that both the characteristics of the blood vessels and the cells are important, and the 
future direction would be to look for the gene expression profile, whether it is associated more 
with MVD or MLN.237,238 The former relates to the host response to the tumor and may not be 
as tightly associated with the gene expression profile, yet most likely involved in the process 
of hematogenous metastasis. Because fresh tumor material is needed for reliable genetic 
analysis, such analysis could not be performed 
Although noninvasive detection of certain extravascular matrix patterns is now technically 
possible124,239,240 in managing patients with UM,241 this study and tumor genetics suggest that 
such noninvasive methods will not fully capture the process of clinical metastasis. Progress in 
resection and biopsy techniques is likely in the near future to result in fresh material for the 
ophthalmic pathologist to correlate angiographic data, histopathological characteristics such 
as MLN, and genetic data. 
 This study supported the theory that tumors containing epithelioid cells grow faster and 
have poorer prognosis27,29-31 when studied by cell proliferation in UM based on Ki-67 
immunoreactivity. Cell proliferation index fitted best with the survival data when combined 
with MVD, MLN, and presence of epithelioid cells. 
The relationship between prognosis and MLN as measured from biopsy and autopsy 
specimens of hepatic metastases was significantly weaker than that of survival and MLN 
Discussion 
 57 
measured from primary tumors. Survival rates after the diagnosis of metastatic disease were 
comparable whether metastases had a high or a low MLN, and MLN in metastatic specimens 
was thus not a useful prognostic indicator.  
Analogous with the finding that high MVD in primary UM is associated with shorter time 
to metastasis than low MVD,30,58,59 high MVD in hepatic metastasis tends to be associated 
with shorter survival after diagnosis of metastasis.203  A future direction would be to measure 
in the clinical settings the MVD of metastasis when planning treatment or estimating the 
prognosis after metastasis, as this is not currently done. 
Because the liver is the main organ for metastasis from UM, growth factors largely 
produced in the liver – hepatocyte growth factor, epidermal growth factor and insulin-like 
growth  factor-1  (IGF-1)  –  together  with  their  receptors  may have  a  role  in  the  homing and  
survival of metastatic cells.152 Therefore the association between immunoreactivity for IGF-
1R in primary UM and metastatic death was studied. It was found that immunoreactivity for 
IGF-IR did not independently predict metastasis from primary UM in my series. Partial loss 
of antigenicity could not be ruled out as a confounding factor because no frozen sections were 
available. Results of earlier studies have likewise been inconsistent, suggesting that 
immunohistochemical determination of IGF-1R from formalin-fixed, paraffin-embedded 
specimens is not practical as a routine test. It may be still useful to test inhibitors of IGF-1R 
clinically in spite of the noncontributory histopathological findings. 
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